A novel synthesis and pharmacological evaluation of a potential dopamine D-1/D-2 agonist: 1-Propyl-1,2,3,4,4a,5,10,10-aoctahydrobenzo[g]quinoline-6,7-diol

Danyang Liu; Durk Dijkstra; Jan B. de Vries; Hakan V. Wikstrom

doi:10.1016/j.bmc.2007.06.036

A novel synthesis and pharmacological evaluation of a potential dopamine D-1/D-2 agonist: 1-Propyl-1,2,3,4,4a,5,10,10-aoctahydrobenzo[g]quinoline-6,7-diol

Danyang Liu, Durk Dijkstra^*, Jan B. de Vries, Hakan V. Wikstrom

^*Corresponding author for this work

Groningen Research Institute of Pharmacy

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

Abstract

Previously, we have demonstrated that enone prodrugs of dopaminergic catecholamines represent a new type of dopamine (DA) agonist. Trans-1-propyl-1,2, 3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diol (TL-334), the active form oftrans-1-propyl-2,3,4,4a,5,7,8,9,10,10a-decahydro-1H-benzo[g]quinolin-6-one (GMC-6650), in vivo showed an extremely potent dopaminergic activity. Here, we report a novel synthesis and a pharmacological evaluation of TL-334 by means of microdialysis. (C) 2007 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	3438-3444
Number of pages	7
Journal	Bioorganic & Medicinal Chemistry
Volume	16
Issue number	6
DOIs	https://doi.org/10.1016/j.bmc.2007.06.036
Publication status	Published - 15-Mar-2008

Keywords

catecholamine
enone prodrug
microdialysis
Parkinson's disease
PARKINSONS-DISEASE
LOCOMOTOR-ACTIVITY
APOMORPHINE
MICRODIALYSIS
STIMULATION
MECHANISMS
DYSKINESIA
ROPINIROLE
BEHAVIOR
PRODRUG

Access to Document

10.1016/j.bmc.2007.06.036

Handle.net

Persistent link

Embargoed Document

A novel synthesis and pharmacological evaluation of a potential dopamine
Final publisher's version, 193 KB
Request copy

Cite this

@article{a6450a75c0b34292a84caf1846b2f50c,

title = "A novel synthesis and pharmacological evaluation of a potential dopamine D-1/D-2 agonist: 1-Propyl-1,2,3,4,4a,5,10,10-aoctahydrobenzo[g]quinoline-6,7-diol",

abstract = "Previously, we have demonstrated that enone prodrugs of dopaminergic catecholamines represent a new type of dopamine (DA) agonist. Trans-1-propyl-1,2, 3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diol (TL-334), the active form oftrans-1-propyl-2,3,4,4a,5,7,8,9,10,10a-decahydro-1H-benzo[g]quinolin-6-one (GMC-6650), in vivo showed an extremely potent dopaminergic activity. Here, we report a novel synthesis and a pharmacological evaluation of TL-334 by means of microdialysis. (C) 2007 Elsevier Ltd. All rights reserved.",

keywords = "catecholamine, enone prodrug, microdialysis, Parkinson's disease, PARKINSONS-DISEASE, LOCOMOTOR-ACTIVITY, APOMORPHINE, MICRODIALYSIS, STIMULATION, MECHANISMS, DYSKINESIA, ROPINIROLE, BEHAVIOR, PRODRUG",

author = "Danyang Liu and Durk Dijkstra and {de Vries}, {Jan B.} and Wikstrom, {Hakan V.}",

year = "2008",

month = mar,

day = "15",

doi = "10.1016/j.bmc.2007.06.036",

language = "English",

volume = "16",

pages = "3438--3444",

journal = "Bioorganic & Medicinal Chemistry",

issn = "0968-0896",

publisher = "PERGAMON-ELSEVIER SCIENCE LTD",

number = "6",

}

A novel synthesis and pharmacological evaluation of a potential dopamine D-1/D-2 agonist: 1-Propyl-1,2,3,4,4a,5,10,10-aoctahydrobenzo[g]quinoline-6,7-diol. / Liu, Danyang; Dijkstra, Durk; de Vries, Jan B. et al.
In: Bioorganic & Medicinal Chemistry, Vol. 16, No. 6, 15.03.2008, p. 3438-3444.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - A novel synthesis and pharmacological evaluation of a potential dopamine D-1/D-2 agonist

T2 - 1-Propyl-1,2,3,4,4a,5,10,10-aoctahydrobenzo[g]quinoline-6,7-diol

AU - Liu, Danyang

AU - Dijkstra, Durk

AU - de Vries, Jan B.

AU - Wikstrom, Hakan V.

PY - 2008/3/15

Y1 - 2008/3/15

N2 - Previously, we have demonstrated that enone prodrugs of dopaminergic catecholamines represent a new type of dopamine (DA) agonist. Trans-1-propyl-1,2, 3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diol (TL-334), the active form oftrans-1-propyl-2,3,4,4a,5,7,8,9,10,10a-decahydro-1H-benzo[g]quinolin-6-one (GMC-6650), in vivo showed an extremely potent dopaminergic activity. Here, we report a novel synthesis and a pharmacological evaluation of TL-334 by means of microdialysis. (C) 2007 Elsevier Ltd. All rights reserved.

AB - Previously, we have demonstrated that enone prodrugs of dopaminergic catecholamines represent a new type of dopamine (DA) agonist. Trans-1-propyl-1,2, 3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diol (TL-334), the active form oftrans-1-propyl-2,3,4,4a,5,7,8,9,10,10a-decahydro-1H-benzo[g]quinolin-6-one (GMC-6650), in vivo showed an extremely potent dopaminergic activity. Here, we report a novel synthesis and a pharmacological evaluation of TL-334 by means of microdialysis. (C) 2007 Elsevier Ltd. All rights reserved.

KW - catecholamine

KW - enone prodrug

KW - microdialysis

KW - Parkinson's disease

KW - PARKINSONS-DISEASE

KW - LOCOMOTOR-ACTIVITY

KW - APOMORPHINE

KW - MICRODIALYSIS

KW - STIMULATION

KW - MECHANISMS

KW - DYSKINESIA

KW - ROPINIROLE

KW - BEHAVIOR

KW - PRODRUG

U2 - 10.1016/j.bmc.2007.06.036

DO - 10.1016/j.bmc.2007.06.036

M3 - Article

SN - 0968-0896

VL - 16

SP - 3438

EP - 3444

JO - Bioorganic & Medicinal Chemistry

JF - Bioorganic & Medicinal Chemistry

IS - 6

ER -

A novel synthesis and pharmacological evaluation of a potential dopamine D-1/D-2 agonist: 1-Propyl-1,2,3,4,4a,5,10,10-aoctahydrobenzo[g]quinoline-6,7-diol

Abstract

Keywords

Access to Document

Handle.net

Embargoed Document

Fingerprint

Cite this